Rani Therapeutics Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development of orally administered biologics to transform medicine and improve patient outcomes. Rani Therapeutics Holdings serves customers in the United States.

424B5 | Prospectus

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Rani Therapeutics Holdings (RANI US)

424B5 | Prospectus

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-06)

Current Report (Form 8-K | Period ending 2025-10-22)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)